EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Rep to Router: A Life-Cycle Channel-Allocation Framework for Pharmaceutical Physician Engagement and Its Implications for Drug Affordability

Daniel Rose

American Impact Review · 18.06.2026 · 1 (6) · e2026049

DOI: 10.66308/air.e2026049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Impact Review, online erschienen am 18.06.2026. Verfasst von Daniel Rose. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmaceutical promotion is among the largest discretionary cost categories in the U.S. health-care economy, and the spending is recovered through the price of medicines. Total U.S. medical marketing reached $29.9 billion by 2016, of which physician-directed promotion was $20.3 billion [11]. The in-person sales visit has lost efficiency: access fell from ~77% of prescribers in 2008 to a pandemic low near 20%, recovering only partially, per ZS Associates AccessMonitor and Veeva Pulse data.

Methods

Narrative review of open-source evidence (peer-reviewed literature, U.S. government data, named-consultancy analyses), modeled on Hashimoto et al. 2024 [1]. Eighteen sources (seventeen with verified DOIs) across six themes.

Results

The evidence converges on several consistent findings: remote detailing can match in-person on outcomes at lower cost [3, 5]; in-person retains an advantage at launch [6, 7]; access is scarce and selective, making segmentation decisive, per Veeva Pulse field data; well-executed hybrid models report 10-20% efficiency gains, by McKinsey and Veeva Crossix analyses. From this the review derives PACE-Rx and applies it to the GLP-1 market.

Conclusions

PACE-Rx offers a replicable model consistent with a lower cost per effective contact; because promotional cost is embedded in drug prices, the efficiency is a plausible lever for restraining U.S. drug costs without curtailing innovation or access.

Zitieren

APA

Rose, D. (2026). From Rep to Router: A Life-Cycle Channel-Allocation Framework for Pharmaceutical Physician Engagement and Its Implications for Drug Affordability. American Impact Review, 1(6), e2026049. https://doi.org/10.66308/air.e2026049

Vancouver

Rose D. From Rep to Router: A Life-Cycle Channel-Allocation Framework for Pharmaceutical Physician Engagement and Its Implications for Drug Affordability. American Impact Review. 2026;1(6):e2026049. doi:10.66308/air.e2026049

BibTeX
@article{Rose2026,
  author = {Rose, Daniel},
  title = {From Rep to Router: A Life-Cycle Channel-Allocation Framework for Pharmaceutical Physician Engagement and Its Implications for Drug Affordability},
  journal = {American Impact Review},
  year = {2026},
  volume = {1},
  number = {6},
  pages = {e2026049},
  doi = {10.66308/air.e2026049}
}
Kostenlos starten →